The Journal of
Clinical Psychiatry

Suicide

Letter to the Editor December 31, 1999

Deliberate Self-Poisoning Following Fluvoxamine-Neuroleptics Combination

Siow-Ann Chong; Andrew Cheong

J Clin Psychiatry 1999;60(12):869

Article Abstract

Letter to the Editor

Sir: Akathisia with suicidal ideation has been reported to be associated with 2 selective serotonin reuptake inhibitors, fluoxetine and sertraline. We report a case of deliberate selfpoisoning following the development of akathisia after the introduction of fluvoxamine treatment.

About the Authors

Download Free PDF

This PDF is free for all visitors!

Save

Cite

Sponsored

PsychCase360: Choosing the Right Long-Acting Injectable for Patients With Schizophrenia

Explore two real-world schizophrenia cases with Roueen Rafeyan, MD and Melissa Vitale, PMHNP as they discuss challenges with medication adherence, transitioning to long-acting injectables (LAIs), and personalizing treatment strategies to improve patient outcomes.

Vol 86 • 2025 • Number 2

Read the Current Issue

Original Research

Incidence and Risk Factors for Suicide Attempt During Pregnancy and Postpartum

Original Research

Valbenazine in Elderly Adults With Tardive Dyskinesia

Academic Highlights

Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report

Original Research

Older Adults Visiting Emergency Departments for Mental Health Issues:A CHIRPP Database Study

Consensus Statement

Developing a Treatment-Resistant Depression Consultation Program, Part I: Practical and Logistical Considerations

Brief Report

Psychosocial Correlates of Optimism among US Military Veterans

View current Issue

Related Articles

Daridorexant: Caution Is Needed About Suicidal Risk in Depressed Patients With Insomnia—Reply to Palagini et al

Letter to the Editor

Daridorexant: Caution Is Needed About Suicidal Risk in Depressed Patients With Insomnia—Reply to Palagini et al

July 3, 2023

Bénédicte Nobile, PharmD, PhD, and Philippe Courtet, MD, PhD, continue the discussion of potentially increased suicidal risk with daridorexant, a new hypnotic.

Bénédicte Nobile, Philippe Courtet

Aggravation of Suicide Risk With Daridorexant: Currently Not Enough Data to Show a Link

Letter to the Editor

Aggravation of Suicide Risk With Daridorexant: Currently Not Enough Data to Show a Link

July 3, 2023

Palagini and colleagues comment on a recent letter that suggested a role for daridorexant, a new hypnotic, in increasing suicide risk.

Laura Palagini, Pierre A. Geoffroy, Jean Arthur Micoulaud-Franchi, et al

Possible Suicidal Risk With Daridorexant

Letter to the Editor

Possible Suicidal Risk With Daridorexant

December 7, 2022

Instructions for use of the new anti-insomnia medication daridorexant mention cautious use in patients with history of suicidal behavior. This letter explores the factors that underlie this recommendation for...

Bénédicte Nobile, Emilie Olié, Philippe Courtet